TY - JOUR
T1 - Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety
AU - Onda, Yuichi
AU - Masuda, Yuichi
AU - Yoshida, Masahito
AU - Doi, Takayuki
N1 - Funding Information:
The authors also thank Prof. Motoki Takagi at Fukushima Medical University for evaluation of sensitivity to different cancer cell lines. Financial contribution from JSPS KAKENHI Grant JP15H05837 in Middle Molecular Strategy, Grant JP26282208, and the Platform Project for Supporting in Drug Discovery and Life Science Research from Japan Agency for Medical Research and Development (AMED) are gratefully acknowledged.
Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/8/10
Y1 - 2017/8/10
N2 - We have demonstrated design, synthesis, and biological evaluation of apratoxin A mimetics. In the first generation, the moCys moiety was replaced with seven simple amino acids as their 3D structures can be similar to that of apratoxin A. Apratoxins M1-M7 were synthesized using solid-phase peptide synthesis and solution-phase macrolactamization. Apratoxin M7, which contains a piperidinecarboxylic acid moiety, exhibited potent cytotoxicity against HCT-116 cells. In the second generation, substitution of each amino acid residue in the tripeptide Tyr(Me)-MeAla-MeIle moiety in apratoxin M7 led to the development of the highly potent apratoxin M16 possessing biphenylalanine (Bph) instead of Tyr(Me), which exhibited an IC50 value of 1.1 nM against HCT-116 cells. Moreover, compared to apratoxin A, apratoxin M16 exhibited a similarly high level of growth inhibitory activity against various cancer cell lines. The results indicate that apratoxin M16 could be a potential candidate as an anticancer agent.
AB - We have demonstrated design, synthesis, and biological evaluation of apratoxin A mimetics. In the first generation, the moCys moiety was replaced with seven simple amino acids as their 3D structures can be similar to that of apratoxin A. Apratoxins M1-M7 were synthesized using solid-phase peptide synthesis and solution-phase macrolactamization. Apratoxin M7, which contains a piperidinecarboxylic acid moiety, exhibited potent cytotoxicity against HCT-116 cells. In the second generation, substitution of each amino acid residue in the tripeptide Tyr(Me)-MeAla-MeIle moiety in apratoxin M7 led to the development of the highly potent apratoxin M16 possessing biphenylalanine (Bph) instead of Tyr(Me), which exhibited an IC50 value of 1.1 nM against HCT-116 cells. Moreover, compared to apratoxin A, apratoxin M16 exhibited a similarly high level of growth inhibitory activity against various cancer cell lines. The results indicate that apratoxin M16 could be a potential candidate as an anticancer agent.
UR - http://www.scopus.com/inward/record.url?scp=85027356651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027356651&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b00833
DO - 10.1021/acs.jmedchem.7b00833
M3 - Article
C2 - 28682609
AN - SCOPUS:85027356651
SN - 0022-2623
VL - 60
SP - 6751
EP - 6765
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 15
ER -